U.S. Markets closed

Sinclair Pharma plc (SPH.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
29.25-0.12 (-0.43%)
At close: 4:30PM BST
People also watch

Sinclair Pharma plc

Whitfield Court
1st Floor
London W1T 2RQ
United Kingdom
44 20 7467 6920

IndustryDrug Manufacturers - Major
Full Time Employees173

Key Executives

Mr. Christopher P. SpoonerChief Exec. Officer and Exec. Director1.09MN/AN/A
Mr. Alan Musgrave Olby ACA, B.A.Chief Financial Officer and Director203kN/A46
Ms. Jayne BurrellGroup Gen. Counsel and Company Sec.N/AN/A42
Mr. Nairn McMasterHead of IntercontinentalN/AN/AN/A
Mr. Louis Derek PayetHead of Europe & APACN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Sinclair Pharma plc, a specialty pharmaceutical company, engages in the manufacture, commercialization, and sale of dermatological products worldwide. It provides Silhouette Soft, a resorbable poly-L-lactic acid(PLLA)/PLGA suture with bi-directional resorbable cones for skin repositioning and tightening; and Ellansé, which offers dermal fillers. The company also provides Perfectha for wrinkle correction, facial contouring, and volume restoration; and Sculptra designed to stimulate collagen growth. It serves healthcare providers and plastic surgeons. The company was formerly known as Sinclair IS Pharma plc and changed its name to Sinclair Pharma plc in December 2015. Sinclair Pharma plc was founded in 1971 and is headquartered in London, the United Kingdom.

Corporate Governance

Sinclair Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.